(Q58861268)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19568285%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

title

Novel therapeutic strategies for multiple sclerosis: potential of intravenous immunoglobulin (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19568285%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19568285%20AND%20SRC:MED&resulttype=core&format=json

Sébastien Lacroix-Desmazes

1 February 2020

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19568285%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Srini V Kaveri

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19568285%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

author name string

Srini V. Kaveri

series ordinal

3

0 references

publication date

1 July 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19568285%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Drug Discovery

1 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19568285%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19568285%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19568285%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

page(s)

594

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19568285%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nrd2358-c1

1 February 2020

exact match

0 references

cites work

Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses

1 reference

https://api.crossref.org/works/10.1038%2FNRD2358-C1

Novel therapeutic strategies for multiple sclerosis--a multifaceted adversary

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD2358-C1

Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: rationale and mechanisms of action.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2358-C1

Drug Insight: the use of intravenous immunoglobulin in neurology--therapeutic considerations and practical issues

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2358-C1

Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2358-C1

Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2358-C1

No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2358-C1

Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2358-C1

Intravenous immunoglobulins in the treatment of relapsing remitting multiple sclerosis--results of a retrospective multicenter observational study over five years

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2358-C1

Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2358-C1

EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2358-C1

Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2358-C1

Rituximab and intravenous immune globulin for desensitization during renal transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2358-C1

Shortage of human intravenous immunoglobulin—reasons and possible solutions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2358-C1

Intravenous immunoglobulin in MS: promise or failure?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD2358-C1